\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesQ2Scale is a tailor-made start-up scaling programme, giving European top technologies in the automotive, energy, supply chain, and sustainability sectors the opportunity to receive a full package for international market penetration and beta testing in a two month hybrid programme.
What the programme offers
REAL-WORLD VALIDATION: Get the opportunity to validate your technology in an industry setting to attract interest and fast-track entry into global markets.
STREAMLINED POC PROCESSES: Equip yourself with the tools and expertise needed to efficiently conduct PoCs with corporations. Ensure a fast-track approach by bypassing red tape and iterating quickly to meet industry needs.
EXPOSURE TO GLOBAL INDUSTRY LEADERS: Forge connections with global industry leaders, unlocking collaboration opportunities. Open doors to potential partnerships and collaborations by networking with global influential industry figures.
ACCESS TO EXPERT MENTORSHIP: Connect with experienced global mentors and technological experts who provide tailored guidance to navigate the complexities of innovation around the world.
CONTINUAL OPPORTUNITIES FOR COLLABORATION AND CONNECTION: Encounter ongoing opportunities for collaboration and connection, ensuring lasting relationships beyond the programme's conclusion.
GLOBAL MARKET INSIGHTS: Gain targeted insights from leading international players into pressing trends in the global market.
Apply now or find more information and apply before the deadline (30/11/2024).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
